An insulin simplification regimen: from multiple injections to once-daily long-acting (basal) insulin plus noninsulin agents. *Basal insulins: glargine.

Slides:

Advertisements

Similar presentations

Advertisements

Insulin therapy.

Inpatient Glycemic Management

Diabetes Update Division of Endocrinology Department of Medicine Wayne State University Medical School Detroit, Michigan Part 3 of 3.

Consider this Combo: GLP-1 Receptor Agonists and Basal Insulin Matt Heinsen, PharmD PGY2 Pharmacotherapy Resident Butler University & Community Health.

New Insulin Formulations Guillermo Umpierrez, MD, FACP, FACE Professor of Medicine Emory University School of Medicine Part 1.

Insulin Glargine (Lantus) Lantus is a long-acting insulin that should be injected below the skin once daily as directed by your doctor. Take Lantus the.

Achieving Glycemic Control in the Hospital Setting

Insulin initiation in Type 2 Diabetes

Diabetes Mellitus Part 2 Kathy Martin DNP, RN, CNE.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes.

Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS.

Representative insulin regimens for the treatment of diabetes

What's New in Basal Insulin for Diabetes

Insulin Type (trade name)

Representative insulin regimens for the treatment of diabetes

Copyright © 2015 by the American Osteopathic Association.

Representative insulin regimens for the treatment of diabetes

Recommendation In people with clinical cardiovascular disease in whom glycemic targets are not met, a SGLT2 inhibitor with demonstrated cardiovascular.

Representative insulin regimens for the treatment of diabetes

Representative insulin regimens for the treatment of diabetes

Representative insulin regimens for the treatment of diabetes

Applying Data to Practice

Insulin Safety know your insulins! There are many! Humalog® Mix25 Humalog® Mix50 Humulin® I Humulin® M3 Humulin® S Humalog® U-100 Humalog® U-200.

T1DM: Insulin Initiation

Figure 4 Amino acid structure of short-acting and long-acting insulins

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Sequential insulin strategies in type 2 diabetes.

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Treatment Pathway for Adults with Type 1 Diabetes

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.

Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).

Figure 2 Pharmacokinetic action profiles of rapid-acting insulins

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Approach to starting and adjusting insulin in type 2 diabetes.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Insulin in Diabetes Management: Effective Patient Selection Is Key

Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial

Glycemic Management in Adults with Type 1 Diabetes

Figure 3 Pharmacodynamic action profiles of long-acting insulins

Nat. Rev. Endocrinol. doi: /nrendo

(A) Kaplan-Meier renal survival estimates of patients with diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and mixed groups, adjusting for.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

(A) 1-year mortality in relation to estimated glomerular filtration rate (eGFR), age (n=47 636) and presence of diabetes mellitus (n=47 624). (A) 1-year.

Evolution of Insulin: From Human to Analog

ADA/EASD general recommendations for type 2 diabetes management (1).

(G) Body mass index (BMI) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (G) Body mass index (BMI) values.

INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.

IGlarLixi SoloSTAR pen device and dose delivery of insulin glargine (units) and lixisenatide (µg) ranging from 15 units insulin glargine/5 µg lixisenatide.

Food intake in response to central infusion of glucose (squares) or insulin (triangles) and in response to successive central infusion of insulin, insulin.

Plasma glucose, GIR, rates of EGP and glucose utilization, and plasma concentrations of free fatty acids (FFAs) and β-hydroxy-butyrate after a subcutaneous.

Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).

ADA type 2 diabetes glycemic control algorithm, reproduced with permission from ref. 4. *Usually a basal insulin (neutral protamine Hagedorn, glargine,

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

Insulin Delivery Systems Atlanta Diabetes Associates

Initiation and adjustment of insulin regimens.

CPPE Optimise: Insulins

Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Glycemic control in Hispanic and non-Hispanic patients during the SWITCH.

A: Detection of insulin aspart and insulin lispro by the Iso-insulin ELISA method. A: Detection of insulin aspart and insulin lispro by the Iso-insulin.

(A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects. (A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects.

Twice daily regimen N=45 MDI regimen N=28 P Value

Time course of daily basal and mealtime insulin dose (A), glycated hemoglobin (B), laboratory-measured clinic FPG (C), prebreakfast SMPG (D), SMPG profiles.

A: Glucose levels during basal-bolus and SSI treatment.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Presentation transcript:

An insulin simplification regimen: from multiple injections to once-daily long-acting (basal) insulin plus noninsulin agents. *Basal insulins: glargine U-100 and U-300, detemir, and degludec. ¥Mealtime insulins (rapid-acting): lispro, aspart, and glulisine. §Mixed insulins: 70/30, 75/25, and 50/50. eGFR, estimated glomerular filtration rate. An insulin simplification regimen: from multiple injections to once-daily long-acting (basal) insulin plus noninsulin agents. *Basal insulins: glargine U-100 and U-300, detemir, and degludec. ¥Mealtime insulins (rapid-acting): lispro, aspart, and glulisine. §Mixed insulins: 70/30, 75/25, and 50/50. eGFR, estimated glomerular filtration rate. Adapted from ref. 30. Erika Leung et al. Diabetes Spectr 2018;31:245-253 ©2018 by American Diabetes Association